CheckMate914

BMS joins Roche on the adjuvant kidney cancer flop list

Enrique Grande on LinkedIn: #immunotherapy

PDF) Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy

ASCO GU 2022: Updates on Clinical Trials in Adjuvant Renal Cell Carcinoma

Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma

EAU 2019: Post-Nephrectomy Adjuvant Therapy for Localized Renal Cell Carcinoma: CheckMate 914 Study of Nivolumab + Ipilimumab in Patients at High Risk of Relapse

CheckMate914

Checkpoint inhibitor immunotherapy in kidney cancer

Home - UROONCO Kidney Cancer

CheckMate 914: Nivo/Ipi in RCC - Slideset Download - ESMO Congress Paris

ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial - The Lancet Oncology

The Search for the Optimal Immunotherapy Sequencing in the Perioperative Setting of RCC

CheckMate914